Cafepharma Today

June 5 2025 - GLP-1 drugs may be linked to elevated risk of serious eye disease, study finds
GLP-1 drugs may be linked to elevated risk of serious eye disease, study finds
Bispecific cancer drugs, data caveats and funding alarms: 3 takeaways from ASCO
FDA’s Elsa AI is here, and the industry has questions
Merck gains U.S. patent office support in Keytruda dispute
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Gilead's 2 hepatitis C drug trials meet study goals
Reuters
Monday, February 4, 2013 - 12:17pm
tags:
Gilead, hepatitis C, Neutrino, Fission
The Medicines Co., Alnylam form strategic alliance to develop RNAi Therapeutics
Yahoo/Fly on the Wall
Monday, February 4, 2013 - 12:14pm
tags:
RNAi, Alnylam, Medicines Company
Trius Therapeutics: Takeover Candidate In 2013
Seeking Alpha
Monday, February 4, 2013 - 12:13pm
tags:
Trius Therapeutics, Cubist Pharmaceuticals, M&A
SciClone Pharmaceuticals: A Promising Biotech Stock
Seeking Alpha
Monday, February 4, 2013 - 12:12pm
tags:
SciClone
Depomed Bear Case: FDA Panel Will Ding Serada
Yahoo/TheStreet.com
Monday, February 4, 2013 - 12:08pm
tags:
Depomed, FDA, Serada
Teva Pharmaceutical Industries Earnings Are on Deck
Motley Fool
Monday, February 4, 2013 - 12:07pm
tags:
Teva, earnings
Big Pharma Is Knocking At Ampio's Door
Seeking Alpha
Monday, February 4, 2013 - 11:58am
tags:
Ampio Pharmaceuticals, JNJ, Regeneron
AstraZeneca Forecasts Lower Profit Amid Generic Pressure
Bloomberg
Monday, February 4, 2013 - 11:39am
tags:
AstraZeneca, generics
Aspen Pharmacare In Talks to Buy Merck & Co. Dutch Unit
Bloomberg
Monday, February 4, 2013 - 11:25am
tags:
Aspen Pharmacare, M&A, South Africa, Merck
GlaxoSmithKline Begins Phase 3 Melanoma Study
Motley Fool
Monday, February 4, 2013 - 11:24am
tags:
GSK, melanoma, BRAF inhibitor, dabrafenid, MEK inhibitor, trametinib
Key TB vaccine trial fails; more waiting in the wings
Reuters
Monday, February 4, 2013 - 11:23am
tags:
tuberculosis, vaccines, Aeras, MVA85A
Aveo Pharma Readies Survival Update For Kidney Cancer Drug
TheStreet.com
Monday, February 4, 2013 - 11:22am
tags:
Aveo Pharmaceutical, kidney cancer, tivozanib
3 Ways to Make Money With Zoetis (Even If You Missed the IPO)
Motley Fool
Sunday, February 3, 2013 - 12:00pm
tags:
Zoetis
Merck Earnings Call Nuggets: Outcome of IMPROVE-IT and Filing Odanacatib
Wall Street Cheat Street
Sunday, February 3, 2013 - 11:59am
tags:
Merck, Odanacatib, osteoporosis, bone cancer
Novartis Recalls OTC Cough Syrups
Motley Fool
Sunday, February 3, 2013 - 11:53am
tags:
Novartis, recalls, Triaminic, Theraflu
US exports may drive top Indian pharmaceutical companies to grow 20 per cent in 2013 BUSINESS
IBN Live, India
Sunday, February 3, 2013 - 11:51am
tags:
Foolish Preview: Gilead Earnings
Motley Fool
Sunday, February 3, 2013 - 11:41am
tags:
Gilead Sciences, earnings
Supernus Launches Oxtellar XR in the United States
Review Seeker
Sunday, February 3, 2013 - 11:40am
tags:
Supernus Pharmaceuticals, Oxtellar XR, epilepsy
Two Biotech Names Without the Microcap Roller Coaster
Motley Fool
Sunday, February 3, 2013 - 11:37am
tags:
Acadia, Depomed
What's Ahead for Exelixis?
Motley Fool
Sunday, February 3, 2013 - 11:36am
tags:
Exelixis

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Not One of Your Easy Crystals
In the Pipeline
The Continuing Crisis, Part XV: The Horrendous Trump Budget
In the Pipeline
Taurine Revisited
In the Pipeline
A New Route to Asthma Treatment - Through the Liver, of All Places
In the Pipeline
One Drug's Supply Chain, In Detail
In the Pipeline
A Reaction to Alzheimer's Fraud
In the Pipeline
Whoa Now: Cautionary Tales from Materials Science
In the Pipeline
Inside a Scientific Paper Mill
In the Pipeline
Autoimmune Disease, Transformed?
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.